REGENXBIO reports interim data for Duchenne gene therapy RGX-202
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
March 11, 2026 11:45 AM EDTInvestigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional measures at 1 year, including participants aged 8+Cardiac MRI data for pivotal dose patients demonstrated stability at 1 yearFavorable safety profile continued with no serious adverse events or adverse events of special interest observed in Phase I/II studyNew data from multiple measures supported liver safety in pivotal patientsPivotal topline data expected Q2... More
